A new report from Nomura suggests that the biotechnology sector in China is entering a period of increased international activity, specifically regarding out-licensing deals with US firms. Jialin Zhang, head of China healthcare research at Nomura, characterized this trend as a "high tide" for the industry, noting that the environment for cross-border collaboration is becoming more favorable.

This outlook is largely driven by the perception that the US government is moving away from implementing sweeping restrictions on Chinese biotech companies. Previously, there was significant market anxiety regarding potential US Treasury Department actions that could have limited investment or cooperation. While the regulatory landscape remains complex, the current consensus among these analysts is that the immediate threat of broad, sector-wide curbs has faded. This development aligns with Beijing’s broader national objectives, which prioritize the expansion and technological advancement of its healthcare industry over the next five years. While the report highlights optimism for deal flow, it does not detail specific companies or the long-term sustainability of these partnerships should political tensions between the two nations resurface.